IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders

September 17, 2024

Overcoming Obstacles to Bring a New Standard of Care

Discover how CRC’s approach helped a biopharma company secure FDA approval for a novel treatment targeting acute agitation in schizophrenia and bipolar disorders. With strong site relationships, rigorous rater training, and expert regulatory guidance, the project team successfully navigated complex conditions, including the challenges posed by the COVID-19 pandemic.

< Older Post

Newer Post >
neural network

Speed Kills: Is Your Neuropsychiatric Trial at Risk?

September 10, 2025
Why do neuropsychiatric trials fail? Experts Dr. Steve Brannan and Dr. David Walling share strategies to protect investments in neuropsychiatric drug development.
Jason Casarella

CRC Appoints Jason Casarella, MBA as Chief Commercial Officer

September 2, 2025
Experienced CRO executive joins Cognitive Research Corporation to expand partnerships and strengthen its position as a leading CRO for CNS clinical trials
psychedelic mushrooms

The Renaissance of Psychedelic Research: History, Protocols, and Forward Trajectories

August 20, 2025
Psychedelic clinical research is advancing. Explore how trials with psilocybin, LSD, MDMA, and DMT are redefining protocols, standards, and future therapies.
Show More